



INSIDE THIS ISSUE

- Benefit Drug List – Anagrelide
- Protocol Update – UBRAJACT, BRAVCLOD, BRAVPAM, LKANAG, LUDOC, OSVIM, SAVIM
- Cancer Management Manual
- Pre-Printed Order Update – UBRAVTR, BRAVCLOD, BRAVPAM, BRAVTRAP, CNCCV, KSLDO, LYCHOP-R, LYCOPP, LYRITUX, MYPAM, PICC
- Patient Education – Anagrelide, Cabergoline, Cancer Drugs
- Drug Update – Anagrelide, BCG Reconstitution Kit, Cabergoline, Valrubicin
- Provincial Systemic Therapy Program Policies – Intrathecal Administration of Cytotoxic Drug
- Supportive Care – Palliative Care Consultation
- Continuing Education – Canadian Association of Nurses in Oncology Conference
- Correction – Rituximab Indications in Benefit Drug List and Class II Form

FAX request form and IN TOUCH phone list are provided if additional information is needed.

BENEFIT DRUG LIST

The following new programs have been funded by the Provincial Systemic Therapy Program effective May 1, 2001:

Anagrelide (Agrylin®) as second-line treatment in patients with thrombocytosis related to a myeloproliferative disorder and inadequate response to or intolerant of hydroxyurea and/or interferon.

This is now approved as a Class II drug on the benefit list. A Class II form must be completed and submitted to the Provincial Systemic Therapy Program before the drug will be dispensed at a regional cancer centre or reimbursed to a community hospital.

Susan O'Reilly, MB, FRCPC
Provincial Systemic Program Leader

The current Benefit Drug List is available on the BCCA Communities Oncology Network website <http://bccancer.com>.

PROTOCOL UPDATE

Protocol codes for treatments requiring "Undesignated Indication" approval prior to use are prefixed with the letter **U**.

- **INDEX to BCCA Protocol Summaries** revised monthly (includes tumour group, protocol code, indication, drugs, last revision date and version)
- **UBRAJACT** revised (eligibility, tests): Adjuvant therapy for breast cancer using doxorubicin and cyclophosphamide followed by paclitaxel.
- **BRAVCLOD** revised (tests): Therapy of bone metastases in breast cancer using oral clodronate.
- **BRAVPAM** revised (tests): Treatment of acute bone pain secondary to breast cancer metastases using pamidronate or IV clodronate.
- **LKANAG** new: Anagrelide as second-line treatment of thrombocytosis related to myeloproliferative disorders
- **LUDOC** revised (deleted bilirubin from tests and dose modifications, deleted exclusion): Second-line treatment for advanced non-small cell lung cancer with docetaxel (Taxotere®)

- **OSVIM** revised (tests, premeds, hydration regimen, precautions, reformatted): Therapy for advanced sarcomas using etoposide, ifosfamide-mesna
- **SAVIM** revised (Day 4 creatinine and lytes added, premedications clarified, treatment plan reformatted): Therapy for newly diagnosed Ewing's sarcoma/peripheral neuroectodermal tumor (PNET) or rhabdomyosarcoma or advanced sarcomas using etoposide, ifosfamide-mesna.

Most protocols are available on the BCCA website <http://www.bccancer.bc.ca/ccp/>.

CANCER MANAGEMENT MANUAL

The Cancer Management Manual is available on BCCA website <http://www.bccancer.bc.ca/cmm/>.

PRE-PRINTED ORDER UPDATE

Pre-printed orders should always be checked with the most current BCCA protocol summaries. The Vancouver Cancer Centre has prepared the following chemotherapy pre-printed orders, which can be used as a guide for reference:

- **UBRAVTR** revised (booking section): Palliative therapy for metastatic breast cancer using trastuzumab (Herceptin®)
- **BRAVCLOD** new (pre-printed orders entitled BRAVCLODIV and BRAVCLODPO): Therapy of bone metastases in breast cancer using oral clodronate
- **BRAVPAM** new: Treatment of acute bone pain secondary to breast cancer metastases using pamidronate or IV clodronate
- **BRAVTRAP** revised (booking section): Palliative therapy for metastatic breast cancer using trastuzumab (Herceptin®) and paclitaxel (Taxol®) as first-line treatment for recurrent breast cancer refractory to anthracycline chemotherapy
- **CNCCV** new: Adjuvant lomustine, cisplatin and vincristine in adult high-risk medulloblastoma or other primitive neuroectodermal tumour (PNET)
- **KSLDO** new (replacing UKSLDO): Therapy for Kaposi's sarcoma using liposomal doxorubicin (Caelyx®)

- **LYCHOP-R** revised: Treatment of lymphoma with doxorubicin, cyclophosphamide, vincristine, prednisone and rituximab
- **LYCOPP** revised (Day 8: CBC & Diff deleted): Treatment of Hodgkin's disease using cyclophosphamide, vincristine, procarbazine and prednisone
- **LYRITUX** revised: Treatment of lymphoma with single agent rituximab
- **MYPAM** revised: Treatment of multiple myeloma with pamidronate
- **PICC** new: Peripherally inserted central catheter (PICC) insertion order

An index to the orders can be obtained by Fax-back.

PATIENT EDUCATION

Anagrelide patient handout is now available via H-drive at regional cancer centres or Fax-back.

Cabergoline patient handout is now available via H-drive at regional cancer centres or Fax-back.

Cancer drugs Patient handouts are available for a number of cancer drugs which are being incorporated into the BCCA Cancer Drug Manual and the website. These are listed at the end of the Update and can be obtained via H-drive at regional cancer centres or Fax-back.

DRUG UPDATE

Anagrelide is an oral agent used for the treatment of thrombocytosis (essential thrombocythemia) in patients with myeloproliferative disorders. It reduces elevated platelet counts and the risk of thrombosis, as well as amelioration of symptoms.

BCG Reconstitution Kit can be purchased from Faulding (Canada) Inc. and is sold separately from BCG. The device is based on a 3-way stopcock (one arm each to syringe, BCG vial and catheter) and is similar to the M.E.R.C.I. device by Organon. BCCA will continue to reimburse the BCG but will not fund the device.

Cabergoline (Dostinex®) inhibits pituitary secretion of prolactin and growth hormone. It has

been used for prolactinoma, pituitary adenoma, and acromegaly. Cabergoline is not on the BCCA Benefit Drug List and reimbursement for its use requires prior "Undesignated Indication" approval.

Valrubicin (Valtaxin® by Paladin Labs Inc) is an anthracycline derivative, which has recently been approved in Canada for intravesicular therapy of BCG-refractory carcinoma in situ of the urinary bladder. The usual dose is to instil 800 mg into the bladder once a week for six weeks. Since the drug is formulated in Cremophor, non-DHEP containing administration kits are required. Valrubicin is available as 200 mg/5 mL vials and the approximate cost is \$1200 per 4 vials.

CANCER DRUG MANUAL

The Cancer Drug Manual is available on the BCCA website <http://www.bccancer.bc.ca/cdm/>.

PROVINCIAL SYSTEMIC THERAPY PROGRAM POLICIES

Intrathecal Administration of Cytotoxic Drugs A policy has been developed and implemented on the administration of cytotoxic drugs by the intrathecal route via lumbar puncture or Ommaya reservoir (Patient Care Policy III-50). This policy provides a systematic method for ordering, preparing, checking, and administering cytotoxic drugs by the intrathecal route.

Other BCCA Systemic Therapy Policies are available at <h:\everyone\systemic\prov\chemo\policies> on the H-drive at the regional cancer centres and on <http://www.bccancer.bc.ca/ccp/appendices.shtml> in the BCCA website:

- Chemotherapy process
- Extravasation of chemotherapy: prevention and management
- Standing orders for specific medications: ambulatory patients in the Systemic Program
- Systemic therapy treatments
- Acute hypersensitivity reactions to chemotherapeutic agents
- Cytotoxic agents: safe handling standards
- Employee health: management of risks related to cytotoxic agents
- Spill management of cytotoxic agents

- Administration of cytotoxic drugs by the intrathecal route via lumbar puncture or Ommaya reservoir
- Labeling of vinca alkaloid syringes

SUPPORTIVE CARE

Palliative Care Consultation A 24-hour every day service for all BC physicians and home care nurses to get expert advice on managing symptoms in terminally ill patients is now available. Callers to a toll free telephone number (1-877-711-5757) will be connected with a palliative care physician who can assist in symptom management, advise of resources in the local area, and provide suggestions for case management. This service is a pilot project of the BC Medical Association Palliative Care Working Group and Vancouver Home Hospice in cooperation with the Ministry of Health.

CONTINUING EDUCATION

Canadian Association of Nurses in Oncology (CANO) Annual Conference will be held in Quebec City on 23-26 September 2001. The theme for this year will be "The Art of Communication: Discovery through Sharing of Stories". For more details, please contact: Canadian Association of Nurses in Oncology, tel: (416) 596-6565, fax: (416) 596-1808, or email: canoacio@interlog.com.

CORRECTIONS

Rituximab Indications in the March and April versions of the Benefit Drug List and Class II Form included "newly diagnosed discordant low grade and diffuse large B cell lymphoma". This is incorrect and will be deleted in the revised 1 May Benefit Drug List and Class II Form.

Editorial Review Board

Mário de Lemos, PharmD (Editor)

Sharon Allan, MD
 Sandi Broughton, BA(Econ), MSc
 Jack Chritchley, MD
 Karen Janes, MSN
 Susan Walisser, BSc(Pharm)
 David Noble, BSc, BLS

Gigi Concon (Secretary)

REGIONAL CANCER CENTRE ACCESS

BULLETIN UPDATES	LOCATION	
Patient Handouts:	H:\everyone\systemic\chemo\Pt_Educ	
	Anagrelide	Letrozole
	Anastrozole	Octreotide (Sandostatin LAR)
	Bicalutamide	Pamidronate
	Capecitabine	Raltitrexed
	Cabergoline	Rituximab
	Clodronate	Temozolomide
	Docetaxel	Topotecan
	Exemestane	Trastuzumab
	Gemcitabine	Vinorelbine
	Irinotecan	
Pre-Printed Orders	H:\everyone\systemic\chemo\Orders\VCC	
Index of Pre-Printed Orders		Index.doc
	UBRAVTR	LYCHOP-R
	BRAVCLOD	LYCOPP
	BRAVPAM	LYRITUX
	BRAVTRAP	MYPAM
	CNCCV	PICC
	KSLDO	
Protocol Summaries	H:\everyone\systemic\chemo\Protocol\tumour site"	
Index of Protocol Summaries		Index_NT or Index_W6
	UBRAJACT	LUDOC
	BRAVCLOD	OSVIM
	BRAVPAM	SAVIM
	LKANAG	
Reimbursement	H:\everyone\systemic\chemo\Reimburs	
Benefit Drug List (01 May 2001)		BenefitList.doc
Class 2 Form (01 May 2001)		Class2.doc

For easy access, double-click your systemic chemo icon.

We appreciate your comments. Write us at bulletin@bccancer.bc.ca

IN TOUCH	www.bccancer.bc.ca	bulletin@bccancer.bc.ca
BC Cancer Agency	(604)-877-6000	Toll-Free 1-(800)-663-3333
Communities Oncology Network	Ext 2744	bfiddler@bccancer.bc.ca
Nursing Professional Practice	Ext 2623	ilundie@bccancer.bc.ca
Pharmacy Professional Practice	Ext 2247	gconcon@bccancer.bc.ca
Provincial Systemic Therapy Program	Ext 2247	gconcon@bccancer.bc.ca
Communities Oncology Network Pharmacist	Ext 2515	francish@bccancer.bc.ca
Drug Information	Ext 3028	robrien@bccancer.bc.ca
Library / Cancer Information	Ext 2690	dnoble@bccancer.bc.ca
Update Editor	Ext 2288	mdelemos@bccancer.bc.ca
Cancer Centre for the Southern Interior (CCSI)	(250) 712-3900	Toll-Free 1-(888)-563-7773
Fraser Valley Cancer Centre (FVCC)	(604)-930-2098	Toll-Free 1-(800)-523-2885
Vancouver Cancer Centre (VCC)	(604)-877-6000	Toll-Free 1-(800)-663-3333
Vancouver Island Cancer Centre (VICC)	(250) 519-5500	Toll-Free 1-(800)-670-3322

BCCA SYSTEMIC THERAPY UPDATE FAX REQUEST FORM

FAX (604) 877-0585

bulletin@bccancer.bc.ca

TO SUBSCRIBE: FAX OR EMAIL YOUR REQUEST OR CALL @ 877-6098 LOCAL 2247

FOR URGENT REQUESTS PLEASE CALL (604) 877-6098 LOCAL 2247

OR TOLL-FREE IN BC 1-800-663-3333 LOCAL 2247

PLEASE FEEL FREE TO MAKE COPIES FOR YOUR COLLEAGUES

I WOULD PREFER TO RECEIVE THIS INFORMATION VIA:

E-mail (Word 6.0)

Fax

@	
()	Attn:

UPDATES Please Fax-Back information below:

<input type="checkbox"/> All items	
Patient Handouts:	
<input type="checkbox"/> anagrelide	<input type="checkbox"/> anastrozole
<input type="checkbox"/> bicalutamide	<input type="checkbox"/> capecitabine
<input type="checkbox"/> cabergoline	<input type="checkbox"/> clodronate
<input type="checkbox"/> docetaxel (Taxotere)	<input type="checkbox"/> exemestane
<input type="checkbox"/> gemcitabine	<input type="checkbox"/> irinotecan
<input type="checkbox"/> letrozole	<input type="checkbox"/> octreotide (Sandostatin LAR)
<input type="checkbox"/> pamidronate	<input type="checkbox"/> raltitrexed
<input type="checkbox"/> rituximab	<input type="checkbox"/> temozolomide
<input type="checkbox"/> topotecan	<input type="checkbox"/> trastuzumab (Herceptin)
<input type="checkbox"/> vinorelbine	<input type="checkbox"/>
Pre-Printed Orders:	
<input type="checkbox"/> UBRAVTR	<input type="checkbox"/> PICC
<input type="checkbox"/> BRAVPAM	<input type="checkbox"/> BRAVCLOD
<input type="checkbox"/> CNCCV	<input type="checkbox"/> BRAVTRAP
<input type="checkbox"/> LYCHOP-R	<input type="checkbox"/> KSLDO
<input type="checkbox"/> LYRITUX	<input type="checkbox"/> LYCOPP
<input type="checkbox"/> Index: Pre-Printed Orders	<input type="checkbox"/> MYPAM
Protocol Summaries:	
<input type="checkbox"/> UBRAJACT	<input type="checkbox"/> SAVIM
<input type="checkbox"/> BRAVPAM	<input type="checkbox"/> BRAVCLOD
<input type="checkbox"/> LUDOC	<input type="checkbox"/> LKANAG
<input type="checkbox"/> Index: Protocol Summaries (current month)	<input type="checkbox"/> OSVIM
Reimbursement	
<input type="checkbox"/> Benefit Drug List (01 May 2001)	
<input type="checkbox"/> Class 2 Form (01 May 2001)	
Systemic Therapy Update Index	
<input type="checkbox"/> Jan-Dec 2000	